Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Most people who struggle with their weight can at least try cutting calories or exercising more. For people with Smith-Magenis syndrome, though, it is not that simple. This rare genetic condition rewires how the brain handles hunger. The urge to eat does not come from bad habits. It comes from the genes themselves.
That is what makes a new case report so interesting. Doctors tracked an 11-month treatment period in a young male patient with Smith-Magenis syndrome. He received daily injections of a weight loss drug called liraglutide. By the end, he had lost 22.2 kilograms, about 49 pounds. The report was published in the journal Cureus. As far as researchers know, only one other published case has ever looked at using a GLP-1 receptor agonist in someone with this condition.
Smith-Magenis syndrome comes from a missing piece of chromosome 17. People with this condition often deal with learning difficulties, sleep problems, and challenging behaviors. One of the hardest symptoms to manage is hyperphagia. This means feeling constantly and overwhelmingly hungry, no matter how much a person eats. Telling someone with this condition to simply eat less is not a realistic solution. The hunger is biological, not behavioral.
This particular patient had been gaining weight steadily for five years before doctors tried medication. By the time treatment started, his health had already taken some hits. He had prediabetes, high cholesterol, and early signs of fatty liver disease. These are serious warning signs, especially in a young person. Doctors felt they needed to act before things got worse.
They turned to liraglutide, a prescription drug the FDA approved for long-term weight management under the brand name Saxenda. The drug works by sending signals to the brain and stomach that say the body is full. It also slows digestion, which helps people feel satisfied longer. Doctors slowly increased the dose over about five months until the patient reached the full daily amount of 3.0 mg.
One big concern going in was side effects. People with Smith-Magenis syndrome often have trouble communicating how they feel. So spotting a bad reaction early is harder than usual. That is why doctors were relieved when the patient handled the full dose without any serious adverse events. That result alone matters a lot for future cases.
The weight loss was also meaningful in size. Losing around 13 percent of total body weight puts this patient in line with results seen in broader GLP-1 clinical trials. Those trials involved people without rare genetic conditions. The fact that the drug worked similarly here suggests it can tackle hunger even when that hunger has a genetic cause, not just a lifestyle one.
The authors are honest about what one case can and cannot tell us. It cannot prove the drug works for everyone with this condition. It also cannot change official prescribing guidelines on its own. But with so little research out there, even a single well-documented success story moves the needle. Other conditions like Prader-Willi syndrome also cause relentless hunger tied to genetics. Doctors treating those patients are watching this area of research closely, too, as interest in GLP-1 drugs for syndromic obesity continues to grow.
For now, this case gives doctors a rare and useful piece of evidence. It does not settle the debate about liraglutide in Smith-Magenis syndrome. But it makes a strong case for taking the question more seriously.
